The Global Intravenous Immunoglobulin (IVIG) Market was valued at $7,861 million in 2015 and is projected to reach $12,632 million by 2022, registering a CAGR of 7.1% from 2016 to 2022. Rise in prevalence of autoimmune disorders across the globe and surge in demand for intravenous immunoglobulin for treating neurological disorders supplement the growth of the IVIG market.
Download Sample Report: https://www.alliedmarketresearch.com/request-sample/325
The market is driven by a number of factors, especially the emergence of myriad antibody deficiency disorders such as common variable immune deficiency (CVID), specific antibody deficiency, and hypogammaglobulinemia as well as rare immune disorders among patient population. Other factors that drive that push the market forward are an increase in immunoglobulin indications, improved production & purification processes, and a growth in awareness toward antibody deficiency. However, market growth faces hindrance from stringent government regulations towards immunoglobulin products and the high risk of side effects with IVIG treatment.
The report offers a detailed segmentation of the global IVIG market based on application, type, and geography. By application, the market is divided into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency disease, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency, Guillain‐Barre syndrome, and others. Hypogammaglobulinemia accounted the largest market share in 2015 and is expected to continue this trend during the forecast period. The growth of this segment is assisted by a large patient population, lack of effective substitute treatment, and early adoption of IVIG to treat the medical disorder.
The global IVIG market is also divided into various types of immunoglobulin, including IgG, IgA, IgM, IgE, and IgD. In 2015, North America accounted for the largest share in the global market, followed by Asia-Pacific in second place. High adoption rate in developed and populous countries such as the U.S. and Japan along with the presence of large plasma production facilities have contributed to the growth of IVIG usability in these regions.
The key companies profiled in the report include
- Baxter International Inc;
- CSL Ltd., Grifols, S.A.;
- Octapharma AG,
- Kedrion Biopharma Inc.,
- LFB Group,
- Biotest AG,
- China Biologics Products, Inc.;
- Shire (Baxalta);
- Bayer AG
For More Information: https://www.alliedmarketresearch.com/connect-to-analyst/325
Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.
Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client’s insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.
5933 NE Win Sivers Drive
#205, Portland, OR 97220
Toll Free: +1-800-792-5285
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060